Cystic Fibrosis News Digest — Issue 01

Grace G Kim, Taryn Wong, Jonathan Rayment, et al.

Summary: Researchers in Canada studied 146 people with cystic fibrosis (CF) before and after one year of taking a drug called elexacaftor/tezacaftor/ivacaftor — often shortened to ETI, a combination treatment that helps the body's defective CF protein work better. Among the 75 participants who had jobs, the amount of work missed due to illness fell from about 13% to 3%. Reduced productivity while at work also dropped significantly, and across all 146 participants, difficulty doing everyday activities fell roughly in half. Improvements in work and daily life tracked closely with how much better people said they felt physically and in terms of breathing.

Why it matters: Clinical trials of CF treatments usually focus on measuring lung function — how much air a person can breathe out. This study looked instead at something patients care deeply about: whether they can show up to work and take part in everyday life. Showing that ETI makes a meaningful difference in these areas — in the real world, not just in a controlled study — helps make the case that the full value of this treatment goes beyond what lung tests capture. For patients, being able to work more consistently and participate more fully in daily activities has real financial and social importance.

What to keep in mind: This study followed people before and after they started ETI, but there was no comparison group of people who did not take it. That means other things happening over the same year — natural changes in health, seasonal variation, or other treatments — could partly explain the improvements. Only 75 of the 146 participants had jobs, which is a relatively small group, and people who were employed at the start may have been healthier than those who were not, making it harder to know how representative the results are. The one-year timeframe also leaves open the question of whether these gains last over many years, which matters greatly for long-term planning and decisions about who should receive the treatment.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42736062/

---

Ashley Han, Matt Hall, Elizabeth Cromwell, et al.

Summary: Researchers linked two large databases — one tracking CF patients across the US and one tracking hospital visits at children's hospitals — to study more than 8,000 children with CF over thirteen years. They used a tool called the Childhood Opportunity Index, which measures how much access a neighborhood provides to good schools, healthcare, clean environments, and economic stability. Children living in neighborhoods with the lowest scores were 60% more likely to be hospitalized for breathing problems than children in the highest-scoring neighborhoods. The pattern held across other types of hospital and emergency room visits as well.

Why it matters: For families and clinicians, this study puts numbers to something many in the CF community already sense: where a child grows up and lives has a measurable effect on how often they end up in hospital. As new CF treatments have become available and dramatically improved outcomes for many children, understanding why some children still face high rates of hospitalization is an urgent and practical question. If neighborhood conditions independently shape a child's risk of serious illness, that has direct implications for how care teams and health systems should plan support.

What to keep in mind: The neighborhood opportunity score is a broad area-level measure — it reflects the average conditions in a zip code or census tract, not what any individual family actually experiences. Two children living in the same neighborhood can have very different home circumstances. The study also cannot rule out the possibility that children in lower-opportunity neighborhoods tend to have more severe CF disease or less access to newer treatments, and those differences — not the neighborhood itself — may partly explain the higher hospitalization rates. The study covers 2009 to 2022, a period that saw the introduction of transformative new CF medicines toward the end. Whether these neighborhood differences in hospitalization have grown smaller, stayed the same, or grown larger since those medicines became widely available is an important question this study cannot answer.

Relevance: CF Registry and Real-World Evidence

Source: https://pubmed.ncbi.nlm.nih.gov/42697797/

---

Marianne S Muhlebach, Jane She, John J LiPuma, et al.

Summary: This study used data from the US CF Foundation Patient Registry, covering roughly 12,000 to 16,000 people with CF each year from 2011 to 2019, to ask whether inhaled antibiotic therapy — long a standard part of CF treatment — is still providing the same benefits now that CFTR modulator medicines have changed the disease landscape. The researchers found that the lung-function benefit of inhaled antibiotics appeared mainly in patients who had a chronic infection with a bacterium called Pseudomonas aeruginosa. In patients without that infection, inhaled antibiotics showed no benefit — and in some cases were linked to worse lung function. Use of inhaled antibiotics was also associated with higher rates of infection from other difficult-to-treat organisms, including a fungus called Aspergillus. Across the years studied, the lung-function benefit of antibiotics appeared to weaken as CFTR modulator use grew.

Why it matters: Inhaled antibiotics have been part of CF care for decades, and many patients take them routinely. But the arrival of CFTR modulators — drugs that treat the underlying cause of CF rather than just the symptoms — has changed what CF looks like for many patients. Fewer patients now develop the chronic Pseudomonas infections that antibiotics were mainly designed to fight. This study raises a practical question: are some patients continuing to take inhaled antibiotics out of established habit when the benefit may no longer outweigh the risk of encouraging other infections? The findings suggest that prescribing decisions may need to be revisited, particularly for patients who do not have chronic Pseudomonas infection.

What to keep in mind: This is an observational study — researchers tracked what happened to patients over time rather than randomly assigning treatments. That means sicker patients were more likely to be prescribed inhaled antibiotics, and differences in how sick patients were at the start may partly explain some of the results, even though the researchers used statistical methods to try to account for this. It is also not possible from this data alone to confirm that the antibiotics caused the infections with other organisms, though there are plausible biological reasons to think they might. Importantly, the data only go up to 2019, before the most powerful current modulator — ETI — was in widespread use. The picture today may look quite different, and the case for re-examining antibiotic prescribing may actually be stronger now. This study builds a credible case for reconsidering standard practices, but it would need to be followed up with studies using more recent data before guidelines change.

Relevance: Cystic Fibrosis | CF Registry and Real-World Evidence

Source: https://pubmed.ncbi.nlm.nih.gov/42767597/

---

Lieke Roeke, Liesbeth I van de Ven, Steffie E M Vonk, et al.

Summary: A Dutch study of 43 people with CF — both children and adults — looked at how well patients were taking their medicines using three different approaches: checking pharmacy records to see how often prescriptions were filled, asking patients directly how consistently they took their medicines, and having pharmacists sit down with patients for detailed structured reviews. The results were striking in two ways. First, patients were much more likely to take their CFTR modulator medicines consistently (72–92% adherence) than they were to take supportive treatments like vitamins, digestive enzymes, and inhaled medicines (56–78%). Second, the structured pharmacist reviews found problems that the other two methods had missed — catching four patients who were not taking medicines as prescribed but had not been identified by pharmacy records or questionnaires, and uncovering 51 medication-related problems across almost all 43 participants. All of those identified problems led to accepted changes in care.

Why it matters: CF requires patients to manage a complex regimen of medicines. In the era of highly effective CFTR modulators, the treatments that directly and dramatically improve how CF feels may understandably feel more important to patients than vitamins or enzymes, even though those supportive treatments remain essential for nutrition, digestion, and lung health. The fact that pharmacy records and patient questionnaires together still missed problems that a pharmacist's detailed review found suggests that care teams may need more than routine data to get a complete picture of how well patients are managing their full treatment plan.

What to keep in mind: This study involved only 43 patients at a single specialist clinic in the Netherlands. Patients who attend a dedicated CF center and agree to participate in a study are likely to be more engaged with their care than average, which means the adherence rates reported here may be higher than what would be found across the broader CF population. The study looked at one point in time, so it cannot show whether the pharmacist reviews actually improved patients' health over time — that would require a longer follow-up study comparing patients who received reviews with those who did not. The finding that every single problem identified by pharmacists was accepted and acted upon by treating doctors is encouraging, but a study this small carried out at one center cannot confirm this would happen everywhere.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42667119/

---